Gerrit A Meijer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7208246/publications.pdf

Version: 2024-02-01

147801 98798 4,980 101 31 67 citations h-index g-index papers 102 102 102 10832 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The earliest events in <scp><i>BRAF</i></scp> â€mutant colorectal cancer: exome sequencing of sessile serrated lesions with a tiny focus dysplasia or cancer reveals recurring mutations in two distinct progression pathways. Journal of Pathology, 2022, 257, 239-249.	4.5	5
2	Genome Nexus: A Comprehensive Resource for the Annotation and Interpretation of Genomic Variants in Cancer. JCO Clinical Cancer Informatics, 2022, 6, e2100144.	2.1	4
3	Reply to R. Pham et al. JCO Precision Oncology, 2022, 6, e2200053.	3.0	O
4	Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance). Epigenetics, 2022, , 1-11.	2.7	0
5	Lessons from a systematic literature search on diagnostic DNA methylation biomarkers for colorectal cancer: how to increase research value and decrease research waste. Clinical and Translational Gastroenterology, 2022, Publish Ahead of Print, .	2.5	1
6	Cell-free DNA (cfDNA) fragmentomes predict tumor burden in metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2022, 40, 3541-3541.	1.6	0
7	High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence. Scientific Reports, 2022, 12, .	3.3	5
8	<i>RNF43</i> mutation analysis in serrated polyposis, sporadic serrated polyps and Lynch syndrome polyps. Histopathology, 2021, 78, 749-758.	2.9	10
9	Driver mutations occur frequently in metastases of wellâ€differentiated small intestine neuroendocrine tumours. Histopathology, 2021, 78, 556-566.	2.9	11
10	Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study. BMC Gastroenterology, 2021, 21, 67.	2.0	2
11	Identification of DNA methylation markers for early detection of CRC indicates a role for nervous system-related genes in CRC. Clinical Epigenetics, 2021, 13, 80.	4.1	22
12	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clinical and Translational Science, 2021, 14, 954-963.	3.1	5
13	An Automated Correction Algorithm (ALPACA) for ddPCR Data Using Adaptive Limit of Blank and Correction of False Positive Events Improves Specificity of Mutation Detection. Clinical Chemistry, 2021, 67, 959-967.	3.2	7
14	The impact of colorectal cancer screening on incidence and stage IV disease in the Netherlands Journal of Clinical Oncology, 2021, 39, 3531-3531.	1.6	0
15	Early detection of lung cancer using cfDNA fragmentation Journal of Clinical Oncology, 2021, 39, 8519-8519.	1.6	3
16	Feasibility of whole-genome sequencing in routine clinical practice Journal of Clinical Oncology, 2021, 39, 3013-3013.	1.6	3
17	Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNA–minus RNA sequencing data. GigaScience, 2021, 10, .	6.4	10
18	Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression. International Journal of Cancer, 2020, 146, 1979-1992.	5.1	32

#	Article	IF	CITATIONS
19	Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE). BMC Medical Genomics, 2020, 13, 169.	1.5	30
20	Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis. Oncolmmunology, 2020, 9, 1832761.	4.6	10
21	Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. BMC Cancer, 2020, 20, 790.	2.6	30
22	Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS z480 and BEAMing. Scientific Reports, 2020, 10, 8122.	3.3	32
23	Can a biomarker triage test reduce colonoscopy burden in fecal immunochemical test screening?. Journal of Comparative Effectiveness Research, 2020, 9, 563-571.	1.4	O
24	Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors. Journal of Clinical Medicine, 2020, 9, 190.	2.4	5
25	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nature Communications, 2020, $11,525$.	12.8	158
26	Gene expression profiles of esophageal squamous cell cancers in Hodgkin lymphoma survivors versus sporadic cases. PLoS ONE, 2020, 15, e0243178.	2.5	2
27	The landscape of genomic copy number alterations in colorectal cancer and their consequences on gene expression levels and disease outcome. Molecular Aspects of Medicine, 2019, 69, 48-61.	6.4	40
28	CD31-positive microvessel density within adenomas of Lynch Syndrome patients is similar compared to adenomas of non-Lynch patients. Endoscopy International Open, 2019, 07, E701-E707.	1.8	3
29	Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population. American Journal of Gastroenterology, 2019, 114, 1909-1918.	0.4	59
30	High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors. Cancer, 2019, 125, 990-999.	4.1	23
31	Molecular profiling of longitudinally observed small colorectal polyps: A cohort study. EBioMedicine, 2019, 39, 292-300.	6.1	13
32	Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas. Cancer Prevention Research, 2018, 11, 403-412.	1.5	15
33	Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment. Gut, 2018, 67, 447-455.	12.1	27
34	Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. Acta Oncol \tilde{A}^3 gica, 2018, 57, 195-202.	1.8	55
35	Consensus molecular subtype classification of colorectal adenomas. Journal of Pathology, 2018, 246, 266-276.	4.5	60
36	Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study. Oncologist, 2018, 23, 1135.	3.7	2

#	Article	IF	Citations
37	MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer. Oncotarget, 2018, 9, 29445-29452.	1.8	9
38	Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: a multicentre cohort analysis. Gut, 2017, 66, 278-284.	12.1	94
39	Early detection: the impact of genomics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 165-173.	2.8	10
40	Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify. Molecular and Cellular Proteomics, 2017, 16, 1850-1863.	3.8	33
41	Direct detection of early-stage cancers using circulating tumor DNA. Science Translational Medicine, 2017, 9, .	12.4	808
42	Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. BMC Cancer, 2017, 17, 112.	2.6	8
43	Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas. Neuro-Oncology, 2017, 19, 546-557.	1.2	86
44	Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening. Annals of Internal Medicine, 2017, 167, 855.	3.9	39
45	Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression. PLoS ONE, 2017, 12, e0174768.	2.5	27
46	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget, 2017, 8, 63140-63154.	1.8	19
47	A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9. Oncotarget, 2016, 7, 2123-2134.	1.8	17
48	Prognostic value of <i>BRAF</i> and <i>KRAS</i> mutation status in stage II and III microsatellite instable colon cancers. International Journal of Cancer, 2016, 138, 1139-1145.	5.1	43
49	<i>WRN</i> Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy. Clinical Cancer Research, 2016, 22, 4612-4622.	7.0	9
50	Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. Acta Oncológica, 2016, 55, 1273-1280.	1.8	62
51	Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence. British Journal of Cancer, 2016, 115, 1565-1574.	6.4	34
52	Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis. Annals of Surgery, 2016, 263, 138-145.	4.2	44
53	The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis. British Journal of Radiology, 2016, 89, 20150910.	2.2	21
54	Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237). Nuclear Medicine and Biology, 2016, 43, 63-72.	0.6	9

#	Article	IF	CITATIONS
55	Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2016, 23, 1601-1608.	1.5	18
56	CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene, 2016, 35, 4191-4199.	5.9	129
57	Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality—Model-Based Exploration of the Serrated Pathway. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 135-144.	2.5	25
58	Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy. Clinical Cancer Research, 2016, 22, 346-356.	7.0	42
59	GeneBreak: detection of recurrent DNA copy number aberration-associated chromosomal breakpoints within genes. F1000Research, 2016, 5, 2340.	1.6	5
60	Genomic profiling of stage II and III colon cancers reveals <i>APC</i> mutations to be associated with survival in stage III colon cancer patients. Oncotarget, 2016, 7, 73876-73887.	1.8	9
61	Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma. Oncotarget, 2016, 7, 44084-44095.	1.8	10
62	Oncogenic Role of miR-15a-3p in 13q Amplicon-Driven Colorectal Adenoma-to-Carcinoma Progression. PLoS ONE, 2015, 10, e0132495.	2.5	22
63	<i>Spectrin Repeat Containing Nuclear Envelope $1 < i>$ and $4 > Forkhead Box Protein E1 < i>$ Are Promising Markers for the Detection of Colorectal Cancer in Blood. Cancer Prevention Research, 2015, 8, 157-164.</i>	1.5	29
64	Semi-supervised adaptive-height snipping of the hierarchical clustering tree. BMC Bioinformatics, 2015, 16, 15.	2.6	11
65	Serrated neoplasia—role in colorectal carcinogenesis and clinical implications. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 401-409.	17.8	149
66	DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach. British Journal of Cancer, 2015, 112, 1105-1113.	6.4	37
67	MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing. Oncogenesis, 2015, 4, e170-e170.	4.9	53
68	Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases: The randomized phase III CAIRO5 study of the Dutch Colorectal Cancer Group Journal of Clinical Oncology, 2015, 33, TPS3622-TPS3622.	1.6	2
69	High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer. PLoS ONE, 2015, 10, e0138141.	2.5	24
70	MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. Oncotarget, 2015, 6, 26278-26290.	1.8	39
71	Comparison of deep sequencing miRNA expression analysis in primary colorectal cancer and paired metastases Journal of Clinical Oncology, 2015, 33, e14682-e14682.	1.6	0
72	Chromosomal Copy Number Aberrations in Colorectal Metastases Resemble Their Primary Counterparts and Differences Are Typically Non-Recurrent. PLoS ONE, 2014, 9, e86833.	2.5	21

#	Article	IF	CITATIONS
73	FocalCall: An R Package for the Annotation of Focal Copy Number Aberrations. Cancer Informatics, 2014, 13, CIN.S19519.	1.9	2
74	Nontemplated Nucleotide Additions Distinguish the Small RNA Composition in Cells from Exosomes. Cell Reports, 2014, 8, 1649-1658.	6.4	484
75	Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases. British Journal of Cancer, 2014, 111, 749-755.	6.4	25
76	Genomic landscape of metastatic colorectal cancer. Nature Communications, 2014, 5, 5457.	12.8	61
77	DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Research, 2014, 24, 2022-2032.	5 . 5	362
78	The role of KCNQ1 in mouse and human gastrointestinal cancers. Oncogene, 2014, 33, 3861-3868.	5.9	93
79	Promoter CpG island methylation of <i>RET</i> predicts poor prognosis in stage II colorectal cancer patients. Molecular Oncology, 2014, 8, 679-688.	4.6	33
80	Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling. Journal of Proteomics, 2014, 99, 26-39.	2.4	81
81	Microsimulation Model For The Assessment Of Personalized Cancer Care: The Mapcca Model Framework. Value in Health, 2014, 17, A562.	0.3	0
82	The Potential of (TARGETED) MR Colonography as a Screening Tool for Colorectal Cancer: A Cost-Effectiveness Analysis. Value in Health, 2014, 17, A631-A632.	0.3	0
83	Long-Term Impact of the Dutch Colorectal Cancer Screening Programme on Cancer Incidence: Exploration of the Serrated Pathway. Value in Health, 2014, 17, A323.	0.3	1
84	Mismatch Repair Status and <i>BRAF</i> Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clinical Cancer Research, 2014, 20, 5322-5330.	7.0	561
85	Focal chromosomal copy number aberrations in cancer—Needles in a genome haystack. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2698-2704.	4.1	55
86	Proteomics of differential extraction fractions enriched for chromatin-binding proteins from colon adenoma and carcinoma tissues. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1034-1043.	2.3	8
87	Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. British Journal of Cancer, 2013, 109, 2445-2452.	6.4	100
88	Focal aberrations indicate <i>EYA2</i> and <i>hsaâ€miRâ€375</i> as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes and Cancer, 2013, 52, 56-68.	2.8	76
89	Molecular markers and the future of colorectal cancer screening. Colorectal Cancer, 2013, 2, 95-97.	0.8	0
90	Tumor, skin, and plasma concentrations of protein kinase inhibitors (PKIs) in patients with advanced cancer Journal of Clinical Oncology, 2013, 31, 11087-11087.	1.6	2

#	Article	IF	CITATIONS
91	Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer Journal of Clinical Oncology, 2013, 31, 3552-3552.	1.6	O
92	Genome-wide methylation profiling to identify potential epigenetic biomarkers associated with response to sunitinib in metastatic renal cell cancer (mRCC) patients (pts) Journal of Clinical Oncology, 2013, 31, 4566-4566.	1.6	1
93	A new spring for Cellular Oncology. Cellular Oncology (Dordrecht), 2011, 34, 1-2.	4.4	0
94	To DNA or not to DNA? That Is the Question, When It Comes to Molecular Subtyping for the Clinic!. Clinical Cancer Research, 2011, 17, 4959-4964.	7.0	21
95	Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. Journal of Pathology, 2010, 221, 411-424.	4.5	39
96	Rapid Quantification of Myocardial Fibrosis: A New Macro-Based Automated Analysis. Analytical Cellular Pathology, 2010, 33, 257-269.	1.4	25
97	Activity-based differentiation of pathologists' workload in surgical pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 623-628.	2.8	18
98	Pla2g2a Attenuates Colon Tumorigenesis in Azoxymethane-Treated C57BL/6 Mice; Expression Studies Reveal Pla2g2a Target Genes and Pathways. Analytical Cellular Pathology, 2009, 31, 345-356.	1.4	2
99	Array Comparative Genomic Hybridization Copy Number Profiling: A New Tool for Translational Research in Solid Malignancies. Seminars in Radiation Oncology, 2008, 18, 98-104.	2.2	45
100	BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Research, 2006, 34, 445-450.	14.5	192
101	Cytogenetic characteristics of oral squamous cell carcinomas in Fanconi anemia. Familial Cancer, 2001, 1, 39-43.	1.9	11